News

FDA Approves Topical Foam for Plaque Psoriasis of the Scalp and Body
By Lori Solomon HealthDay ReporterTUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
Dermatology Advisor14h
Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body
The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.
The American Journal of Managed Care8d
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis
Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...
Medscape8d
FDA Expands Approval of Roflumilast Foam for Treating Scalp, Body Psoriasis
The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...
Healio8d
FDA approves Zoryve foam 0.3% for scalp, body psoriasis
The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...
Nasdaq8d
Arcutis Biotherapeutics Receives FDA Approval for Once-Daily ZORYVE Foam for Scalp and Body Plaque Psoriasis Treatment
Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.
Monthly Prescribing Reference8d
Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body
Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque ...